David Mack/Photo Researchers, Inc. Since 1998, when 18-year-old Jesse Gelsinger died in a clinical trial at the University of Pennsylvania, the news on gene therapy hasn't gotten much better. In a ...

If, as expected, they prove safer and provide longer lasting therapeutic gene expression, adenovirus vectors like the one that killed Jesse Gelsinger will likely be phased out for most diseases. Why ...

met on 8–10 December to examine the clinical trial in which Jesse Gelsinger became the first person to die from the experimental technique of gene therapy. The RAC responded to his death by ...